欢迎来到天天文库
浏览记录
ID:55683649
大小:588.99 KB
页数:4页
时间:2020-05-24
《超声引导下经皮肝穿射频消融治疗肝癌的临床疗效观察.pdf》由会员上传分享,免费在线阅读,更多相关内容在行业资料-天天文库。
1、临床军医杂志2014年7月第42卷第7期ClinJMedOffic,Vo1.42,No.7,July,2014·697·超声引导下经皮肝穿射频消融治疗肝癌的临床疗效观察刘倚河,毕建民,吴秀艳,廖瑞真,刘舜辉,王莉,秦青秀[解放军第175医院(厦门大学附属东南医院)超声科,福建漳州363000]摘要:目的探讨超声引导下经皮肝穿射频消融治疗肝癌的临床疗效及安全性。方法回顾性分析108例原发或转移性、肿瘤直径<5am的肝癌患者,在超声引导下经皮肝穿单极或双极射频消融治疗的临床资料,检查术后不良反应及并发症发生情况。治疗后30min其中62例患者69个结节行超声造影检
2、查评估疗效,随访观察术前血清AFP升高者血清AFP水平变化、复发情况及1、2、3年生存率。结果108例患者经射频消融治疗后并发症发生率:感染和发热66.7%(72/108),疼痛35.2%(38/108),肝功能~过性异常80.6%(87/108),胸腔积液3.7%(4/108);无手术死亡、腹腔出血、针道转移、邻近脏器损伤等严重并发症。69例术前血清AFP升高[(632±58.35)L]者术后1个月均下降[(132±47.24)g/L],其中41例降至正常水平。1、2、3年生存率分别为84.3%、61.1%、53.7%。结论射频消融治疗肝癌具有创伤小、对肝功
3、能影响小、恢复快、操作简便,可补充或多次治疗,为不能手术切除的肝癌患者提供了一种更安全、有效的治疗方法。关键词:肝肿瘤;射频消融;超声造影中图分类号:R735.7文献标志码Adoi:10.3969/j.issn.1671-3826.2014.07.12文章编号:1671-3826(2014)07-0697-04ClinicalcurativeefectofultrasoundguidedpercutaneousradiofrequencyablationonhepatocellularcarcinomaLiuYi-he,BiJianmin,WuXiuyan,L
4、iaoRuizhen,LiuShunhui,WangLi,QinQingxiu[DepartmentofUltrasonography,PLA175thHospital(AffiliatedSoutheastHospitalofXiamenUniversity),ZhangzhouFujian363000,China]Abstract:ObjectiveToinvestigatetheclinicalefficacyandsafetyofpercutaneousradiofrequencyablationguidedbyultrasoundinthetreat
5、mentoflivercancer.MethodsAretrospectiveanalysiswasdoneon108patientswithprimaryormetastatichepatocel—lularcarcinoma(diameter<5cm).Theyunderwentpercutaneoustranshepaticradiofrequencyablation(unipolarorbipolar)guidedbyultrasound.Thirtyminuteslater,theefficacywasevaluatedaccordingto69no
6、dulesundergoingcontrast-enhancedultra-soundin62patients.ResultsAftertreatment,infectionandfeveroccu~edin66.7%(72/108),painin35.2%(38/108),transientabnormalliverfunctionin80.6%(87/108),andpleura1effusionin3.7%(4/108);therewerenooperationdeath,ab·dominalbleeding,pintractmetastasisanda
7、djacentviscerainjury.The69patientswithincreasedpreoperativeserumAFPlevel(at632±58.35tLg/L)gotadecreaseinthelevel(to132±47.24L)onemonthafteroperation,andin41ofthemthelevelde-creasedtonormalleve1.Thesurvivalratesof1-,2-and3-yearwere84.3%,61.1%and53.7%.ConclusionRadiofrequencyablationi
8、nthetreatmentoflive
此文档下载收益归作者所有